<DOC>
	<DOCNO>NCT02265796</DOCNO>
	<brief_summary>This prospective , double-blind , placebo-controlled , randomize , single-center ( North Florida- South Georgia VA Medical Center ) study . The study objective determine ranolazine improve angina symptoms 4 month compare placebo among stable coronary artery disease patient demonstrable myocardial ischemia , undergo revascularization</brief_summary>
	<brief_title>Improvement Subjective Well-Being Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients</brief_title>
	<detailed_description>This prospective , double-blind , placebo-controlled , randomize , single-center ( North Florida- South Georgia VA Medical Center ) study . The study objective determine ranolazine improve angina symptoms 4 month compare placebo among stable coronary artery disease patient demonstrable myocardial ischemia , undergo revascularization . Baseline Procedure : Assessments perform exclusively determine eligibility study would do obtain informed consent . Assessments perform clinical indication ( exclusively determine study eligibility ) may use baseline value even study do informed consent obtain . The assessment include : - Informed Consent - Review subject eligibility criterion - FFR value calculate time cardiac catheterization - Review previous concomitant medication - Frequency symptom quality life prior study accord Seattle Angina Questionnaire ( SAQ ) Screening Visit : The assessment determine eligibility : - Review eligibility criterion - Review cardiac catheterization FFR - Review medication take past 30 day Subjects meet eligibility criterion randomize receive either active drug , Ranolazine match placebo ( non-active drug ) . Staff subject know subject receive active drug placebo . Drug schedule follow : - 1st dose one tablet ( 500mg ) begin even Day 1 - On Days 2-7 , one tablet ( 500mg ) two time day ( 12-hours apart ) . - On Day 8 , increase dose study drug two tablet ( 1000mg ) twice day ; morning evening , 12 hour apart . This dose continue duration study . The study drug take without food . Telephone Follow-up : One week phone call make determine well , adverse event , answer question remind subject increase study medication dose . Month 4 Follow-up : - Frequency symptom quality life accord Seattle Angina Questionnaire ( SAQ ) - Assessment well-being - Any hospitalization need revascularization</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Adult patient &gt; = 18 year age refer cardiac catheterization evaluation cardiac symptom ( angina , fatigue , shortness breath ) At least 1 indeterminate stenosis ( 2080 % ) , Fractional flow reserve ( FFR ) &lt; =0.8 PCI defer Coronary revascularization ( percutaneous coronary intervention coronary artery bypass graft ) index procedure anticipate within next month acute coronary syndrome cardiogenic shock QTc &gt; 500 millisecond use strong inhibitor CTP3A ( i.e . ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir saquinavir ) use inducer CYP3A ( i.e . rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's wort ) liver cirrhosis sever renal insufficiency ( i.e . creatinine clearance &lt; 30mL/min/1.73 m2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>defer percutaneous coronary intervention</keyword>
	<keyword>fractional flow reserve</keyword>
</DOC>